Literature DB >> 16342060

A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).

Antony C Bakke1, Zoe Purtzer, Jose Leis, James Huang.   

Abstract

Since Zap-70 expression in chronic lymphocytic leukemia (CLL) cells correlates with a lack of somatic mutation of the immunoglobulin variable heavy chain (IgVH) genes, it has been proposed as a surrogate marker for disease prognosis. However, published studies of Zap-70 expression have used different commercial antibodies and analytic strategies. This study was undertaken to determine if any strategy was broadly applicable in a clinical flow cytometry laboratory. Expression of Zap-70 was determined in 37 CLL patients using four different commercial antibodies. T, NK, and CLL cells were identified by immunophenotyping along with Zap-70 expression. Data was analyzed in terms of both percent of CLL cells expressing Zap-70 and the ratio of Zap-70 expression in CLL cells compared to that in T + NK cells. Three Zap-70 antibodies showed wide ranges of Zap-70 expression as a percentage of tumor cells, while a fourth gave consistently elevated results. Comparing the percent Zap-70 expression with any two antibodies gave poor correlations (r(2) = 0.45-0.63). Our results indicated that the previous analytical strategies were not reproducible. A ratio metric is proposed, which gave better correlations (r(2) as high as 0.95) and would allow separation of CLL patients with elevated or decreased Zap-70 expression. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16342060     DOI: 10.1002/cyto.b.20079

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  6 in total

1.  Combined normal donor and CLL: Single tube ZAP-70 analysis.

Authors:  Heba A Degheidy; David J Venzon; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2011-10-26       Impact factor: 3.058

Review 2.  Detection methods of ZAP-70 in chronic lymphocytic leukemia.

Authors:  Yin-Hua Wang; Lei Fan; Wei Xu; Jian-Yong Li
Journal:  Clin Exp Med       Date:  2011-06-21       Impact factor: 3.984

3.  Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.

Authors:  Heba A Degheidy; David J Venzon; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2011-04-06       Impact factor: 3.058

4.  Methodological comparison of two anti-ZAP-70 antibodies.

Authors:  Heba A Degheidy; David J Venzon; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2011-04-06       Impact factor: 3.058

5.  Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Authors:  Francesca M Rossi; Maria Ilaria Del Principe; Davide Rossi; Maria Irno Consalvo; Fabrizio Luciano; Antonella Zucchetto; Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Marco Fangazio; Dania Benedetti; Massimo Degan; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2010-03-08       Impact factor: 5.531

6.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Authors:  Joan H Admirand; Ronald J Knoblock; Kevin R Coombes; Constantine Tam; Ellen J Schlette; William G Wierda; Alessandra Ferrajoli; Susan O'Brien; Michael J Keating; Rajyalakshmi Luthra; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.